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Introduction
Gastric cancer is the second leading cause of cancer-associated death worldwide [1, 2] . Although surgical treatment is effective for gastric cancers in the early stage, in the advanced stages total gastrectomy and extended radical gastrectomy are often required but lead to poor prognosis due to post-surgical recurrence in the form of lymphatic spread, blood-borne metastasis, or peritoneal dissemination [1] . Scirrhous gastric carcinoma, a diffusely infiltrating type of poorly differentiated gastric carcinoma, is characterized by rapid cancer cell infiltration and proliferation accompanied by extensive stromal fibrosis [3] . Scirrhous gastric carcinoma accounts for approximately 10%
of gastric carcinomas, and shows an extremely poor 5-year survival rate, compared with that of other types of gastric carcinomas [4] . Common features of scirrhous gastric cancer include progressive invasion and frequent metastasis to the peritoneum [5] . These points differ from intestinal types of gastric cancer [6] .
Although attempts have been made to use chemotherapy, hormonal therapy, hyperthermia and immunotherapy to prevent peritoneal dissemination from scirrhous gastric carcinoma, these therapies were not effective [7] . There is thus a longstanding need for novel therapies based on the biological characteristic of scirrhous gastric cancer.
MicroRNAs (miRNAs) have received significant attention as a new class of non-coding RNAs engaged in the regulation of gene expression [8, 9] . miRNAs are short 18-25 nucleotide stretches of RNA that bind to the target mRNAs and suppress their translation or initiate decay [9] . miRNAs exhibit differential expression in cancers and play important roles in their progression and metastasis [10, 11] . Recently, we identified various miRNAs [12] associated with peritoneal dissemination using our orthotopic inoculation models [13, 14] . In subsequent studies, we used our two established parent cell lines (HSC-44PE and HSC-58) from individual scirrhous gastric cancer patients [13] , and further isolated two clones (44As3 and 58As9) with a highly metastatic character [14] from the corresponding parental cells.
The results of an miRNA array among the above four lines showed that the miR-516a-3p levels were significantly lower in both of the metastatic lines than in their parent lines [12] . A stable line of 44As3 cells exhibiting ectopic overexpression of the miRNA miR-516a-3p (44As3-miR-516a-3p) exhibited decreased cell proliferation, migration, and invasion in vitro, and also decreased ascites fluid and peritoneal dissemination upon orthotopic inoculation into nude mice, when compared with an empty vector-inoculated group [12] . Further, This method is useful for constitutive upregulation of miRNA levels in tumors via an artificial vector.
Materials and Methods

Cancer cells
HSC-58 cells were previously established from a scirrhous gastric cancer patient [13] . Orthotopic transplantation of HSC-58 cells into BALB/c nude mice (male, 6-weeks-old: Japan SLC, Hamamatsu, Japan) resulted in peritoneal dissemination (including to the omentum or mesenterium), and ascites in a small number of mice.
Twelve cycles of i) isolation and ii) orthotopic transplantation of the tumor cells from ascites were vigorously repeated. In this way, a metastatic cell line (58As9) with a strong capacity for inducing ascites and strong peritoneal dissemination properties was successfully isolated [14] . All of the cells were cultured in RPMI 1640 supplemented with 10% FBS [13, 14] .
RNA isolation
Total RNA was extracted from the cells or tumor tissues using TRIzol Reagent (Invitrogen), and the quality of the total RNA was evaluated by an Agilent 2100
Bioanalyzer (Agilent). The total RNA extracted was fractionated and cleaned up with a flashPAGE fractionator system (Ambion) to obtain pure miRNAs.
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Quantitative real-time RT-PCR for miRNA (qRT-PCR)
TaqMan ® MicroRNA Assays (Applied Biosystems) were performed to quantitate the expression levels of mature miRNAs as described previously [12] . For the reverse-transcription step (10 ng total RNA per sample), a TaqMan ® microRNA RT kit (Applied Biosystems) was used. All of the PCR reactions were run using a StepOne™ real-time PCR system (Applied Biosystems).
The data on each row were processed by the Ct method [17] .
Stable ectopic overexpression of miR-516a-3p in 58As9
The vector to express hsa-miR-516a-3p
(1 g; Takara Bio, Shiga, Japan) was transfected into 58As9 cells using a Lipofectamine 2000 reagent as reported previously [12] . Details about this vector are given in Figure 1 . The vector-transfected cells were selected with Geneticin ® (100 g/ml), and a stable clone (termed 58As9-miR 516a-3p) that exhibited overexpression of miR-516a-3p was obtained. Research Institute or at Nagoya University Graduate School of Medicine.
Luciferase reporter assay
58As9-miR-516a-3p cells were seeded in six-well plates (1.5×10 5 per well) and cultured for one day before transfection. The cells were then transfected with a pGL3
vector alone (Promega), the vector with SULF1-3'-UTR, or the vector with SULF1-3'-UTR but with mutation as reported previously [12] . A pRLTK vector (0.1 g; Promega) was co-transfected in order to normalize the transfection efficiency.
Whole cell lysates with RIPA buffer (Thermo Scientific) were prepared 48 h after the transfection, and the Firefly and Renilla luciferase activities were assayed using a Dual-Luciferase Reporter assay kit (Promega) [12] .
Medical Research Archives, Vol. 5, Issue 7, July 2017 The microRNA miR-516a-3p regulates the Wnt pathway by targeting extracellular sulfatase 1 in human scirrhous gastric cancers: Anti-metastatic therapy via miRNA-based medicine Fermentas Life Sciences, York, UK) according to the manufacturer's protocol.
Human Wnt3a and -catenin
ELISA
The amount of secreted Wnt3a or the amount of -catenin was determined using an ELISA kit for human Wnt3a (MyBioSource, Inc., San Diego, CA), or DuoSet ® IC human total -catenin ELISA kit (R&D Systems, Minneapolis, MN), respectively.
TCF/LEF reporter assay
To monitor the activity of the Wnt signal-transduction pathway in the cells, a Cignal ™ TCF/LEF Reporter Assay kit was used (SABiosciences, Frederick, MD). Atelocollagen is commercially available from Koken (Tokyo, Japan).
Quantitative real-time RT-PCR for human SULF1
Preparation of the miR-516a-3p expression vector/atelocollagen complex
To prepare the plasmid DNA vector/atelocollagen complex, equal volumes of atelocollagen in PBS and plasmid DNA solution were mixed by rotation for 20 min at 4°C [25] .
Anti-metastasis therapy
58As9 cells (1.5×10 6 cells) were orthotopically inoculated into the stomach wall of 6-week-old BALB/c nude mice (Japan SLC) as described previously [14] .
The cells were solved in 50 l of RPMI 1640 medium. Fifteen days later (day 0), intratumor (it) injection of the miR-516a-3p expression vector/atelocollagen mixture (total volume, 20 l) was performed under 
Statistical analysis
The data were analyzed using the Mann-Whitney U test. Probability values of less than 0.05 were considered to indicate significant differences.
Results
miR-516a-3p expression vector. In our previous study [12] , we showed that the miR-516a-3p level was significantly reduced in 58As9 compared with HSC-58 cells.
Accordingly, we used 58As9 cells to prepare a line that stably and ectopically overexpressed this miRNA, and designated it 58As9-miR-516a-3p [12] . Our vector system for overexpression of miR-516a-3p is shown in Figure 1 , along with the detailed nucleotide sequences of miR-516a-3p.
In vivo phenotypes of 58As9-miR-516a-3p in nude mice.
Quantitative RT-PCR revealed the successful overexpression of the miRNA miR-516a-3p in 58As9 cells [12] . In an in vitro study, 58As9-miR-516a-3p cells showed a significant decrease in cell proliferation, migration, and invasion compared with 58As9 cells stably transfected with the empty vector [12] . In this article, to examine in vivo phenotypes, we orthotopically inoculated cells of the 58As9-miR-516a-3p line into the stomach wall of nude mice. Twenty-five days later, we observed a reduction in tumor formation in the mice (Figure 2A ). Of note, among the 58As9-miR-516a-3p-inoculated mice, only 3 of the 11 mice that formed tumors harbored ascites (Figure 2A) . We also observed a reduction in peritoneal metastasis to the omentum or mesenterium in the mice inoculated with 58As9-miR-516a-3p ( Figure   2A ). The primary tumors derived from 58As9-miR-516a-3p were significantly smaller than those derived from 58As9, or from 58As9-empty vector (p<0.01, Figure   2B ). The mice that harbored tumors derived from 58As9-miR-516a-3p survived for a significantly longer period of time compared with those harboring tumors derived from 58As9 or from the 58As9-empty vector (p<0.01, Figure 2C ).
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(stably miR-516a-3p-overexpressing 58As9 cells). A, Decreased tumor formation, ascites, and peritoneal dissemination to the omentum and mesenterium in the miRNA-overexpressing cells. Each cell was orthotopically inoculated into the nude mice, and 25 days later, all of the mice were sacrificed. In each group, 15 mice were used. B, Primary tumor growth. **, p<0.01. C, Survival period (days) of the nude mice. On day 0, we also inoculated four kinds of cells into the stomach wall of nude mice (n=15 nude mice in each group). **, p<0.01.
Medical Research Archives, Vol. 5, Issue 7, July 2017 The microRNA miR-516a-3p regulates the Wnt pathway by targeting extracellular sulfatase 1 in human scirrhous gastric cancers: Anti-metastatic therapy via miRNA-based medicine miR-516a-3p directly targets extracellular sulfatase 1 (SULF1). We showed by a luciferase reporter assay in 58As9 that the miRNA directly targeted SULF1 ( Figure 3A) . Quantitative RT-PCR revealed that SULF1 expression was significantly reduced in concert with overexpression of miR-516a-3p ( Figure 3B ). Figure   4B ). The TCF/LEF activity was high in 58As9 cells, but was significantly decreased in 58As9-miR-516a-3p cells compared to 58As9-empty vector (p<0.01, Figure 4C ).
miR-516a-3p vector-based anti-metastatic therapy.
To examine the feasibility of using the miRNA-expression vector for anti-metastatic therapy, we injected the vector complexed with atelocollagen into 58As9 orthotopic tumors in nude mice.
Atelocollagen was used as a delivery vehicle for the miRNA-expression vector into the cells [12, 25] . The therapeutic procedures are shown in Figure 5A . When we injected the vector with atelocollagen into the 58As9 tumors, the expression levels of the miRNA were increased and the levels of SULF1 were decreased ( Figure 5B ). Both changes in expression levels were significant (p<0.01).
Using our therapy protocol, the survival period of the treated mice became significantly longer than that of the control group mice ( Figure 5C ).
Discussion
Although tumor metastasis accounts for 90% of cancer-related deaths [31, 32] , most existing cancer therapies were not developed to specifically block the metastasis process. Medical Recently, a specialized family of miRNAs, which Hurst et al. named metastamir [10] , has been shown to have proand antimetastatic effects [11, 33] . In a previous report [12] , we identified many miR-516a-3p directly targeted SULF1
in both the 58As9 ( Figure 3 ) and 44As3 [12] cell lines, and these highly metastatic derivatives maintained a high amount of Atelocollagen was used as a reagent to deliver the plasmid DNA into tumors [12] .
We observed increased expression of CD44 and cyclin D1 as a result of TCF/LEF activation via -catenin accumulated in the nucleus in the highly metastatic cell lines.
The increase of cyclin D1 explicitly demonstrates the cell proliferation advantages of the highly metastatic cell lines compared with the corresponding parental lines. We have previously shown that these two metastatic lines proliferate more rapidly than the corresponding parental lines [14] .
CD44, which is a major adhesion protein on the extracellular matrix, is involved with not only physiological processes including leukocyte homing and activation, and wound healing, but also tumor cell invasion and metastasis [28, 35, 36] . Now, it is clear that elevated CD44 is closely associated with cancer metastasis [28, 35, 36] . Thus, the highly metastatic cell lines acquire a suitable microenvironment for metastasis and dissemination of cancer cells, via elevated expression of the -catenin target gene CD44.
CD44 is also known as a marker of tumor-initiating cells (TICs) in various cancers, including gastric cancers [37] . TICs have been defined as a selected population of tumor cells that grow on serial transplantation in xenogeneic models [35] . TICs, like stem cells, are highly resistant to apoptosis and are thought to be essential for metastasis [35] .
Indeed, in our experiments the highly metastatic lines revealed a high tumor formation ratio in nude mice upon orthotopic inoculation, and thus the elevation in CD44
caused by activation of the Wnt--catenin pathway has the potential to confer the characteristic of "stemness" observed in TICs to the highly metastatic lines. In any case, additional investigations using our models will be necessary to elucidate the mechanism connecting peritoneal dissemination and
TICs.
In conclusion, we showed that miR-516a-3p regulates the canonical Wnt pathway by directly targeting SULF1, which is an enzyme that liberates ECM-bound Wnt ligands into the medium in human scirrhous gastric cancers. Further, we demonstrated that miR-516a-3p can be targeted in anti-metastatic therapy for inhibiting the peritoneal dissemination of gastric cancers.
